Mineralys Therapeutics In... (MLYS)
NASDAQ: MLYS
· Real-Time Price · USD
14.51
0.38 (2.69%)
At close: Aug 15, 2025, 3:59 PM
14.52
0.10%
After-hours: Aug 15, 2025, 04:20 PM EDT
Mineralys Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
Revenue | 34K | 34K | 34K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 43K | 52K | 45K | 28K | 17K | 8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -9K | -18K | -11K | -28K | -17K | -8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -203.07M | -201.49M | -192.4M | -168.35M | -134.51M | -105.08M | -84.66M | -66.95M | -48.1M | -38.85M | -31.48M | -28.55M | -21.13M | -14.65M | -7.08M |
Interest Income | 12.3M | 12.97M | 14.59M | 15.1M | 14.84M | 14.28M | 12.76M | 10.37M | 7.6M | 4M | 1.68M | 741K | n/a | n/a | n/a |
Pretax Income | -190.77M | -188.51M | -177.81M | -153.25M | -119.67M | -90.8M | -71.9M | -56.58M | -40.5M | -34.84M | -29.8M | -27.81M | -21.13M | -14.65M | -7.08M |
Net Income | -190.77M | -188.51M | -177.81M | -153.25M | -119.67M | -90.8M | -71.9M | -56.58M | -40.5M | -34.84M | -29.8M | -27.81M | -21.13M | -14.65M | -7.08M |
Selling & General & Admin | 28.36M | 25.78M | 23.81M | 20.64M | 18.3M | 16.25M | 14.3M | 12.46M | 10.05M | 7.08M | 5.23M | 3.51M | 2.14M | 1.26M | 467K |
Research & Development | 174.71M | 175.71M | 168.58M | 147.7M | 116.21M | 88.82M | 70.36M | 54.49M | 38.05M | 31.77M | 26.25M | 25.05M | 18.99M | 13.39M | 6.62M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 1K | 1K | 1K | 1K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 203.07M | 201.49M | 192.4M | 168.34M | 134.51M | 105.07M | 84.66M | 66.95M | 48.1M | 38.85M | 31.48M | 28.55M | 21.13M | 14.65M | 7.08M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | -8K | -8K | -8K | -8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 203.09M | 201.51M | 192.43M | 168.35M | 134.51M | 105.08M | 84.66M | 66.95M | 48.1M | 38.85M | 31.48M | 28.55M | 21.13M | 14.65M | 7.08M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 65.45M | 53.16M | 49.96M | 49.81M | 49.36M | 44.9M | 40.09M | 39.93M | 39.76M | 24.76M | 5.21M | 5.18M | 5.14M | 5.12M | 5.06M |
Shares Outstanding (Diluted) | 65.45M | 53.16M | 49.96M | 49.82M | 49.36M | 44.9M | 40.09M | 39.93M | 39.75M | 24.76M | 5.21M | 5.18M | 5.15M | 5.12M | 5.06M |
EPS (Basic) | -3.56 | -3.73 | -3.64 | -3.27 | -2.71 | -2.19 | -2 | -3.13 | -3.85 | -4.8 | -5.77 | -5.43 | -4.14 | -2.88 | -1.4 |
EPS (Diluted) | -3.56 | -3.73 | -3.64 | -3.27 | -2.71 | -2.19 | -2 | -3.13 | -3.85 | -4.8 | -5.77 | -5.43 | -4.14 | -2.88 | -1.4 |
EBITDA | -203.04M | -201.45M | -192.36M | -168.32M | -134.5M | -105.07M | -84.66M | -66.95M | -40.68M | -31.43M | -16.49M | -13.56M | -13.56M | -7.08M | -7.08M |
EBIT | -199.59M | -201.49M | -192.4M | -168.35M | -134.51M | -105.08M | -84.66M | -66.95M | -48.1M | -38.85M | -31.48M | -28.55M | -21.13M | -14.65M | -7.08M |
Depreciation & Amortization | 41K | 50K | 43K | 71.81K | 21.23K | 134.31K | 126.31K | 10.09M | 17.55M | 23.91M | 31.48M | 28.55M | 21.13M | 14.65M | 7.08M |